Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Ellie (Eleanor) Barnes

BSc. MBBS. PhD, FRCP. FMedSci.


Professor of Hepatology and Experimental Medicine

  • Ludwig Adjunct Scholar

I lead an established research group with a focus on applied immunology relevant to liver disease, including cancer, and I seek to translate laboratory and clinical findings through to human experimental medicine studies.

My group is developing T cell pan-genotypic vaccines for hepatitis C virus (HCV) prevention and hepatitis B virus (HBV) cure using simian adenoviral and other viral vectors. We are also assessing COVID vaccines in disease cohorts. A major challenge for HCV vaccine development is the significant viral diversity both within the same host and between hosts – though parts of the viral genome are conserved, making these excellent T cell targets in the context of a T cell vaccine. Some of the technologies we are developing include integral genetic adjuvants that will have applicability in a broad range of diseases.

More recently, my group has developed national and international programmes in stratified medicine in the UK and S.E. Asia. I led STOP-HCV, a UK-wide MRC-funded stratified medicine consortium (22 partners) that united clinicians, scientists and industry partners in studies of personalised medicine (STOP-HCV.ox.ac.uk/home). The consortium developed high-throughput viral sequencing, integrating these with host genetic analysis, RNA sequencing in blood and liver, immune parameters and blood biomarkers to give new insights into pathogenesis and to use these parameters to identify patients with HCV who will develop hepatocellular liver cancer (HCC) and other negative clinical outcomes. Building on STOP-HCV and my experience in liver disease and immunology, I am now leading the CRUK-funded DeLIVER programme that will develop and test early detection methodologies for the identification of HCC.  

I lead additional programmes of work in immune-mediated liver disease. One of these, IgG4-related disease (of unknown aetiology), affects multiple organs and includes severe biliary and pancreatic pathology, characterised by a lymphocytic infiltrate with IgG4-producing B cells. We have established a large cohort of patients and a national registry (funded through EASL) and are currently performing detailed assessment of T and B cells profiles to further define pathogenesis. 

My group is developing liver imaging techniques with the Oxford Centre for Clinical Magnetic Resonance Research for the non-invasive detection of organ fibrosis and inflammation.

As NIHR CLRN lead for hepatology in the Thames Valley I oversee a portfolio of clinical studies relating to gastroenterology and hepatology at the Oxford University NHS Trust, Oxford.

Phase-I vaccine laboratory at the Peter Medawar buildingPhase-I vaccine laboratory at the Peter Medawar building

Key publications

Recent publications

More publications